1. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS)
   Jing Huang et al, 2022, International Journal of Clinical Pharmacy CrossRef
2. Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
   Li-Chung Chiu et al, 2021, Vaccines CrossRef
3. In vitro investigation of the binding characteristics of dacomitinib to human α 1-acid glycoprotein: Multispectral and computational modeling
   Zhe-Ying Hu et al, 2024, Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy CrossRef
4. Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance study
   Min Zhao et al, 2023, Expert Opinion on Drug Safety CrossRef
5. Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review
   Tomasz Marjanski et al, 2021, International Journal of Molecular Sciences CrossRef
6. Targeting Wnt/Beta-Catenin Signaling in HPV-Positive Head and Neck Squamous Cell Carcinoma
   Faris F. Brkic et al, 2022, Pharmaceuticals CrossRef
7. Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study
   Yihan Liu et al, 2022, Frontiers in Pharmacology CrossRef
8. Real-World Treatment and Outcomes of ALK-Positive Metastatic Non–Small Cell Lung Cancer in a Southeast Asian Country
   Mau Ern Poh et al, 2023, Cancer Management and Research CrossRef
9. Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice
   Paul Hofman, 2021, Cells CrossRef
10. Cardiac arrhythmias associated with anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)
    Feifei Wang et al, 2023, Expert Opinion on Drug Safety CrossRef